Bispecific Antibody Therapies in Multiple Myeloma

home / case-based-digest / bispecific-antibody-therapies-in-multiple-myeloma

As part of the Community Case Forum series, key opinion leaders and participants discuss the use of bispecific antibodies the treatment of patients with multiple myeloma.

hand drawing arrows on chalk board

High-Risk Myeloma Treatment Is Not One-Size-Fits-All

Brielle Benyon;Kristie L. Kahl
Published: October 17th 2024 | Updated: December 17th 2024

“Treatment effectiveness can have different meanings to patients,” a physician assistant said when discussing therapy for high-risk myeloma.

multiple myeloma on tablet

Talquetamab May Be Underutilized in Relapsed/Refractory Myeloma

Brielle Benyon
October 15th 2024

A poll of experts revealed that few are utilizing talquetamab for patients with pretreated relapsed/refractory myeloma.

blood cells

BCMA-Targeted Bispecific Antibodies Are ‘Encouraging’ for Some With Myeloma

Brielle Benyon
September 13th 2024

A group of oncology advanced practice providers discussed the use of BCMA-targeted bispecific antibodies for patients with relapsed/refractory multiple myeloma.

myeloma cells

AE Profile of Bispecific Antibodies Can Be Predictable in Myeloma Management

Brielle Benyon
September 13th 2024

Both community and academic nurses must know what to expect and how to react to adverse events from bispecific antibody treatment in myeloma; however, Donna Catamero, ANP-BC, OCN, CCRC, notes this can be predictable for providers.